Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy

Last updated: May 10, 2024
Sponsor: Prof. Dr. med. Ingo Eitel
Overall Status: Active - Recruiting

Phase

N/A

Condition

Circulation Disorders

Treatment

ICD/CRT-D implantation

Clinical Study ID

NCT04558723
20-275
CMR-ICD-DZHK23
  • Ages > 18
  • All Genders

Study Summary

Patients with diagnostic CMR images for assessment of LGE/fibrosis and evidence/presence of non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups in a 1:1 ratio: ICD group or Optimal HF care group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • NIDCM (idiopathic or familial)*

  • LVEF ≤35% and presence of fibrosis on CMR

  • Diagnostic CMR scan

  • Age ≥18 years

  • Written informed consent

  • Ability to give informed consent

Exclusion

Exclusion Criteria:

  • ICM [previous myocardial infarction, previous percutaneous coronary intervention]

  • Other cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic rightventricular cardiomyopathy, restrictive cardiomyopathy, infiltrativecardiomyopathies [e.g. cardiac amyloidosis, cardiac sarcoidosis, hemochromatosis andiron overload cardiomyopathy], left ventricular non-compaction cardiomyopathy,reversible cardiomyopathies [Takotsubo syndrrome, peripartum cardiomyopathy,chemotherapy induced cardiomyopathy].

  • Myocarditis

  • Contraindication for CMR at study entry (including severe claustrophobia, pacemakeror ICD, metallic cerebral or intracranial implants, known allergy to gadolinium)

  • Severe renal insufficiency (creatinine clearance <30 mL/min)

  • Current pacemaker or defibrillator in situ

  • Current indication for device therapy (e.g. secondary prophylaxis after aborted SCD)

  • Renal impairment defined as an eGFR <30 milliliters

  • Age <18 years

  • Patients presenting with pregnancy

  • Patients without informed consent

  • Participation in another randomized trial

  • Life expectancy <2 years

Study Design

Total Participants: 760
Treatment Group(s): 1
Primary Treatment: ICD/CRT-D implantation
Phase:
Study Start date:
January 14, 2021
Estimated Completion Date:
November 30, 2027

Study Description

The primary objective of this study is to evaluate the hypothesis that implantable cardioverter defibrillator (ICD) therapy would decrease the risk of death from any cause in comparison to optimal heart failure (HF) care without ICD insertion in patients with NIDCM, left ventricular ejection fraction (LVEF) ≤35% and presence of myocardial fibrosis on cardiac magnetic resonance (CMR) imaging.

Connect with a study center

  • Universität zu Lübeck

    Lübeck, Schleswig-Holstein 23538
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.